Works by Zhongjun Xia

Results: 44
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 4, p. 571, doi. 10.1002/ajh.26826
    By:
    • Xu, Wei;
    • Zhou, Keshu;
    • Wang, Tingyu;
    • Yang, Shenmiao;
    • Liu, Lihong;
    • Hu, Yu;
    • Zhang, Wei;
    • Ding, Kaiyang;
    • Zhou, Jianfeng;
    • Gao, Sujun;
    • Xu, Bing;
    • Zhu, Zunmin;
    • Liu, Ting;
    • Zhang, Huilai;
    • Hu, Jianda;
    • Ji, Chunyan;
    • Wang, Shunqing;
    • Xia, Zhongjun;
    • Wang, Xin;
    • Li, Yan
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18

    Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 1, p. 1, doi. 10.1002/cncr.35665
    By:
    • Cai, Zhen;
    • Xia, Zhongjun;
    • He, Ai‐Li;
    • Dong, Yu‐Jun;
    • Wang, Yafei;
    • Liao, Aijun;
    • Song, Yang;
    • Song MM, Juanjuan;
    • Uhlar, Clarissa;
    • Chastain, Katherine;
    • Watkins, Latisha;
    • Luo, Xinchao;
    • Huang, Lin;
    • Niu, Zhuolu;
    • Quijano Cardé, Natalia A.;
    • Guo, Yue;
    • Xu, Hongmei;
    • Verona, Raluca I.;
    • Zhou, Longen;
    • Li, Jingyun
    Publication type:
    Article
    19

    Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.

    Published in:
    2022
    By:
    • Qiu, Lugui;
    • Xia, Zhongjun;
    • Fu, Chengcheng;
    • Chen, Wenming;
    • Chang, Chunkang;
    • Fang, Baijun;
    • An, Gang;
    • Wei, Yongqiang;
    • Cai, Zhen;
    • Gao, Sujun;
    • Weng, Jianyu;
    • Chen, Lijuan;
    • Jing, Hongmei;
    • Li, Fei;
    • Liu, Zhuogang;
    • Chen, Xiequn;
    • Liu, Jing;
    • Wang, Aihua;
    • Yu, Yang;
    • Xiang, Wenxi
    Publication type:
    journal article
    20
    21
    22
    23
    24

    Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.

    Published in:
    Annals of Hematology, 2020, v. 99, n. 11, p. 2589, doi. 10.1007/s00277-020-04234-9
    By:
    • Li, Jing;
    • Bao, Li;
    • Xia, Zhongjun;
    • Wang, Sili;
    • Zhou, Xin;
    • Ding, Kaiyang;
    • Zhang, Wenhao;
    • Yang, Wei;
    • Li, Bingzong;
    • Fu, Chengcheng;
    • Chen, Bing;
    • Hua, Luoming;
    • Wang, Liang;
    • Luo, Jun;
    • Yang, Yang;
    • Xu, Tianhong;
    • Wang, Weida;
    • Huang, Yun;
    • Wu, Guolin;
    • Liu, Peng
    Publication type:
    Article
    25
    26
    27

    Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High‐Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 20, p. 1, doi. 10.1002/cam4.70270
    By:
    • Liang, Dong;
    • Li, Xiaojin;
    • Bai, Shenrui;
    • Wang, Qiaoli;
    • Zeng, Min;
    • Feng, Demei;
    • Lu, Bo;
    • Li, Xiaoqing;
    • Sun, Zhiqiang;
    • Li, Jianyun;
    • Zhou, Huanhuan;
    • Zhang, Jialu;
    • Chen, Xiaoqin;
    • Xia, Zhongjun;
    • Liang, Yang;
    • Wang, Hua
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    P-192: Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02319-3
    By:
    • Wenming Chen;
    • Zhongjun Xia;
    • Baijun Fang;
    • Chengcheng Fu;
    • Wei Li;
    • Linhua Yang;
    • Xiaoyan Ke;
    • Hua Jiang;
    • Jianyu Weng;
    • Li Liu;
    • Yaozhong Zhao;
    • Xuejun Zhang;
    • Aichun Liu;
    • Zhongxia Huang;
    • Qingzhi Shi;
    • Yuhuan Gao;
    • Xiequn Chen;
    • Ling Pan;
    • Zhen Cai;
    • Zhao Wang
    Publication type:
    Article
    41

    P-160: Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma: results of a prospective multicenter clinical trail.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S123, doi. 10.1016/S2152-2650(21)02287-4
    By:
    • Li Bao;
    • Minqiu Lu;
    • Peng Liu;
    • Junling Zhuang;
    • Mei Zhang;
    • Zhongjun Xia;
    • Zhenling Li;
    • Hongmei Jing;
    • Yin Wu;
    • Wen ming Chen;
    • Hebing Zhou;
    • Yuping Gong;
    • Rong Fu;
    • Zhenyu Yan;
    • Wenrong Huang;
    • Bin Chu;
    • Yutong Wang;
    • Yongqing Zhang
    Publication type:
    Article
    42
    43
    44

    Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11489-8
    By:
    • Xia, Zhongjun;
    • Leng, Yun;
    • Fang, Baijun;
    • Liang, Yang;
    • Li, Wei;
    • Fu, Chengcheng;
    • Yang, Linhua;
    • Ke, Xiaoyan;
    • Jiang, Hua;
    • Weng, Jianyu;
    • Liu, Li;
    • Zhao, Yaozhong;
    • Zhang, Xuejun;
    • Huang, Zhongxia;
    • Liu, Aichun;
    • Shi, Qingzhi;
    • Gao, Yuhuan;
    • Chen, Xiequn;
    • Pan, Ling;
    • Cai, Zhen
    Publication type:
    Article